Navigation Links
New model for probing antidepressant actions
Date:2/18/2011

The most widely prescribed antidepressants medicines such as Prozac, Lexapro and Paxil work by blocking the serotonin transporter, a brain protein that normally clears away the mood-regulating chemical serotonin. Or so the current thinking goes.

That theory about how selective serotonin reuptake inhibitors (SSRIs) work can now be put to the test with a new mouse model developed by neuroscientists at Vanderbilt University.

These mice, described in the online edition of the Proceedings of the National Academy of Sciences (PNAS), express a serotonin transporter that has been genetically altered so that it does not respond to many SSRIs or cocaine.

In addition to testing the theory about how SSRIs work, the new mouse model could lead to the development of entirely new classes of antidepressant medications, said Randy Blakely, Ph.D., Allan D. Bass Professor of Pharmacology and Psychiatry at Vanderbilt and senior author of the PNAS paper.

"Many antidepressants have been shown to target other proteins besides the serotonin transporter and their efficacy in treating depression takes many weeks to develop," Blakely said. "There is likely a lot that we don't know about how these drugs act."

To generate the mouse model, Blakely and colleagues at Vanderbilt and the University of Texas Health Science Center at San Antonio first determined exactly which parts of the serotonin transporter protein interact with SSRIs. They took advantage of the fact that the fruit fly expresses a serotonin transporter that is relatively insensitive to the drugs.

By changing the protein's amino acid building blocks, they converted parts of the human serotonin transporter into its fruit fly equivalent, and in so doing identified the single amino acid required for potent binding to many SSRIs as well as to cocaine.

As predicted, the genetically-modified mice displayed normal serotonin transporter levels, and their transporter exhibited normal activity in clearing serotonin from the synapses between nerve cells. But the mice did not respond to Prozac or Lexapro, indicating that the transporter is indeed the specific target of these medications for blocking serotonin inactivation.

"Interestingly, one SSRI, paroxetine (Paxil), retains its normal powerful action on the transporter, revealing that -- at a molecular level -- different antidepressants interact with the transporter in different ways," Blakely said.

The researchers are now evaluating chronic administration of SSRIs to determine how much the transporter contributes to the more clinically relevant, delayed effects of these drugs, as well as for the side effects experience with antidepressant medications.

Because the serotonin transporter in the mouse also lost cocaine sensitivity, the model also may help researchers determine exactly how cocaine acts in the brain. "Perhaps what started as a hunt for better ways to treat depression may also spill over into a better understanding of addiction," Blakely said.


'/>"/>

Contact: Bill Snyder
bill.snyder@vanderbilt.edu
615-322-4747
Vanderbilt University Medical Center
Source:Eurekalert

Related medicine news :

1. Speedy generic approval may not benefit consumers as much as expected, Rotman model shows
2. Speedy generic approval may not benefit consumers as much as expected, Rotman model shows
3. Weight-Loss Surgery May Remodel Heart
4. UNC researchers developing computer models for pediatric airway problems
5. Breathing easy: LSU biochemists offer first 3-D model of asthma-causing inflammation enzyme
6. Transplanted human placenta-derived stem cells show therapeutic potential in stroke models
7. WSU researchers apply fatigue model to fatal commuter air crash
8. Researchers discover way to halt lung inflammation in animal models
9. Embryonic stem cells help deliver good genes in a model of inherited blood disorder
10. Tutorial addresses multi-cell, multi-scale modeling
11. Model predicts a drugs likelihood of causing birth defects
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... ... 2017 , ... Only two months after the official release of The Private ... (France), XO Private has initiated a second print-run of its lavish luxury travel coffee ... across when open, weighs in at more than six kilos, retails at EUR 1,000 ...
(Date:2/24/2017)... ... ... Dr. Ronald E. Hawkins, vice president for academic affairs ... Bell, DO, MBA, HPF, FACOEP-dist., FACEP, as the new dean of Liberty ... to Liberty from the Ohio University Heritage College of Osteopathic Medicine (OU-HCOM), where ...
(Date:2/24/2017)... ... ... With millions of Americans and people worldwide struggling with ... aware of our options and are empowered with strength and information throughout the ... newest edition of "Vision and Hearing" in USA Today, that will educate readers ...
(Date:2/24/2017)... ... February 24, 2017 , ... With ProGlass Prism users ... X . Users have total control over position, rotation, distortion, edge softness, edge blur, ... Final Cut Pro X. , With ProGlass Prism users are given the tools ...
(Date:2/24/2017)... IL (PRWEB) , ... February 24, 2017 , ... The ... the 7th annual “Imagine Me Beyond What You See” body image mannequin art competition. ... Choice will be showcased and the winner revealed at the 31st annual iaedp Symposium, ...
Breaking Medicine News(10 mins):
(Date:2/27/2017)... and PETACH TIKVAH, Israel , ... (NASDAQ: BCLI), a leading developer of adult stem cell ... June S. Almenoff , M.D., Ph.D., FACP, and ... Board of Directors.  "Dr. Almenoff and ... appointments come at an exciting time for our company," ...
(Date:2/24/2017)... Following receiving CE Marking in ... AMAR is a major milestone for the country where the device was ... market in Israel   ... for inclusion in the National Health Basket , Israel ... E-QURE Corp. (OTCQB: EQUR), a leader in medical devices for the treatment of advanced ...
(Date:2/24/2017)... , Feb 24, 2017 Research and Markets ... Strategies - 2016" report to their offering. ... The latest research Hemophilia Drugs Price Analysis and ... Hemophilia market. The research answers the following questions: ... clinical attributes? How are they positioned in the Global Hemophilia market? ...
Breaking Medicine Technology: